Related Experiment Video

Updated: Jul 13, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

Endpoints for clinical trials in young children with cystic fibrosis

Stephanie D Davis1, Alan S Brody, Mary J Emond

  • 1Division of Pulmonology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. sddavis@med.unc.edu

Proceedings of the American Thoracic Society
|July 27, 2007
PubMed

Insights

Developing reliable outcome measures for pediatric cystic fibrosis (CF) lung disease is crucial for clinical trials. Advances in lung function testing and imaging offer new endpoints to improve long-term prognosis for young children with CF.

Area of Science:

  • Pediatric Pulmonology
  • Clinical Trial Methodology
  • Cystic Fibrosis Research

Background:

  • Quantifying lung disease in young children with cystic fibrosis (CF) historically lacked sensitive and reproducible measures.
  • This deficiency hindered the development of effective clinical trials for this vulnerable population.
  • Advances are needed to establish reliable endpoints for early intervention.

Purpose of the Study:

  • To review the current status of outcome measures for pediatric lung disease in cystic fibrosis (CF).
  • To identify key physiologic, anatomic, and bronchoscopic measures suitable for clinical trials in children under 6 years.
  • To highlight the need for standardized definitions and further development of endpoints.

Main Methods:

  • Literature review of recent advancements in pediatric CF outcome measures.
  • Analysis of infant and preschool lung function testing.
  • Evaluation of computed tomography (CT) and bronchoalveolar lavage (BAL) markers.

Main Results:

  • Significant progress has been made in developing and standardizing lung function tests for young children.
  • Computed tomography (CT) and bronchoalveolar lavage (BAL) offer valuable insights into lung pathology and inflammation.
  • Standardization of pulmonary exacerbation definitions for this age group is still lacking.

Conclusions:

  • Established and emerging outcome measures show promise as clinical trial endpoints for pediatric CF.
  • Further refinement and standardization of these measures are essential for future intervention trials.
  • Improved outcome measures will facilitate earlier and more effective treatments to enhance long-term prognosis in young CF patients.

More Related Videos

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD)09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD)

Published on: September 13, 2018

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...